US characterization of focal hepatic lesions with intermittent high-acoustic-power mode and contrast material

Academic Radiology

Volumn 10, Issue 7, 2003, Pages 739-750

  Quaia, Emilio ^a   Bertolotto, Michele ^a   Calderan, Loretta ^a   Mosconi, Elisa ^a   Mucelli, Roberto Pozzi ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Contrast media; Diagnosis; Liver neoplasms; Microbubbles; Ultrasound (US); US

Indexed keywords

CONTRAST MEDIUM; IOMEPROL; IOMERON 300; SONOVUE; SULFUR HEXAFLUORIDE;

ACOUSTICS; ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BOLUS INJECTION; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LIVER HEMANGIOMA; LIVER HYPERPLASIA; LIVER INJURY; LIVER METASTASIS; LIVER TUMOR; MALE; PRIORITY JOURNAL; ULTRASOUND;

EID: 0037785133     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1076-6332(03)80119-8     Document Type: Article

References (26)

1. Wang LY, Wang JH, Lin ZY, et al. Hepatic focal nodular hyperplasia: findings on color Doppler ultrasound. Abdom Imaging 1997; 22:178-181.
2. Lee MG, Auh YH, Cho KS, Chung YH, Lee IC, Kang AEM. Color Doppler flow imaging of hepatocellular carcinomas: comparison with metastatic tumors and hemangiomas by three-step grading for color hues. Clin Imaging 1996; 20:199-203.
3. Hosten N, Puls R, Bechstein WO, Felix R. Focal liver lesions: Doppler ultrasound. Eur Radiol 1999; 9:428-435.
4. Harvey CJ, Blomley MJK, Eckersley RJ, Cosgrove DO. Developments in ultrasound contrast agents. Eur Radiol 2001; 11:675-689.
5. Correas JM, Bridal L, Lesavre A, et al. Ultrasound contrast agents: properties, principles of action, tolerance, and artifacts. Eur Radiol 2001; 11:1316-1328.
6. Hosten N, Puls R, Lemke AJ, et al. Contrast-enhanced power Doppler sonography: improved detection of characteristic flow patterns in focal liver lesions. J Clin Ultrasound 1999; 27:107-115.
7. Uggowitzer M, Kugler C, Groll R, et al. Sonographic evaluation of focal nodular hyperplasia (FNH) of the liver with a transpulmonary contrast agent (Levovist). Br J Radiol 1998; 71:1026-1032.
8. Ramnarine K, Leen E, Oppo K, et al. Improved characterization of focal liver tumours: dynamic power Doppler imaging using NC 100100 echo-enhancer. Eur J Ultrasound 2000; 11:95-104.
9. Kim TK, Han JK, Kim AY, et al. Limitations of characterization of hepatic hemangiomas using an ultrasound contrast agent (Levovist) and power Doppler ultrasound. J Ultrasound Med 1999; 18:737-747.
10. Blomley MJK, Sidhu PS, Cosgrove DO, et al. Do different types of liver lesions differ in their uptake of the microbubble contrast agent SH U 508A in the late liver phase? early experience. Radiology 2001; 220:661-667.
11. Wilson SR, Burns PN, Murdali D, et al. Harmonic hepatic ultrasound with microbubble contrast agent: initial experience showing improved characterization of hemangioma, hepatocellular carcinoma, and metastasis. Radiology 2000; 215:153-161.
12. Burns P, Wilson S, Simpson D. Pulse inversion imaging of liver blood flow: improved method for characterizing focal masses with microbubble contrast. Invest Radiol 2000; 35:58-71.
13. Bertolotto M, Dalla Palma L, Quaia E, Locatelli M. Characterization of unifocal liver lesions with pulse inversion harmonic imaging after Levovist injection: preliminary results. Eur Radiol 2000; 9:1369-1376.
14. Kim TK, Choi BI, Han JK, et al. Hepatic tumors: contrast agent-enhancement patterns with pulse inversion harmonic US. Radiology 2000; 216:411-417.
15. Dill-Macky M, Burns P, Khalili K, Wilson S. Focal hepatic masses: enhancement patterns with SH U 508A and pulse inversion US. Radiology 2002; 222:95-102.
16. Girard MS, Baker KG, Steinbach GC, Deiranieh LH, Peterson TM, Mattrey RF. Assessment of liver and kidney enhancement with a perfluorocarbon vapor-stabilized US contrast agent. Acad Radiol 1999; 6:273-281.
17. Girard MS, Kono Y, Sirlin CB, Baker KG, Deiranieh LH, Mattrey RF. B-mode enhancement of the liver with microbubble contrast agent: a blinded study in rabbits with VX2 tumors. Acad Radiol 2001; 8:734740.
18. Schneider M, Arditi M, Barrau MB, et al. BR1: a new ultrasonographic contrast agent based on sulphur hexafluoride-filled microbubbles. Invest Radiol 1995; 30:451-457.
19. Schneider M. SonoVue, a new ultrasound contrast agent. Eur Radiol 1999; 9(suppl 3):S347-S348.
20. Morel DR, Schwieger I, Hohn L, et al. Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging. Invest Radiol 2000; 35:80-85.
21. Correas JM, Burns PN, Lai X, Qi X. Infusion versus bolus of an ultrasound contrast agent: in vivo dose-response measurements of BR1. Invest Radiol 2000; 35:72-79.
22. Leen E, Becker D, Bolondi L, et al. Prospective, open label multi-centre study comparing the accuracy of unenhanced versus SonoVue enhanced ultrasonography in the characterization of focal liver lesions (abstr). Eur Radiol 2003; 13(suppl 1):270.
23. Sirlin CB, Girard MS, Baker KG, Steinbach GC, Deiranieh LH, Mattrey RF. Effect of acquisition rate on liver and portal vein enhancement with microbubble contrast. Ultrasound Med Biol 1999; 25:331-338.
24. Merritt CR, Forsberg F, Shi WT, Clark H, Goldberg BB. The mechanical index: an inappropriate and misleading indicator for destruction of ultrasound microbubble contrast agents (abstr). Radiology 2000; 217(P):395.
25. Wei K, Ragosta M, Thorpe J, et al. Noninvasive quantification of coronal blood flow reserve in humans using myocardial contrast echocardiography. Circulation 2001; 103:2560-2565.
26. Ruppert-Kohlmayr AJ, Uggowitzer MM, Kugler C, Zebedin D, Schaffler G, Ruppert GS. Focal nodular hyperplasia and hepatocellular adenoma of the liver: differentiation with multiphasic helical CT. AJR Am J Roentgenol 2001; 176:1493-1498.